Intrastriatal injection of ionomycin profoundly changes motor response to l-DOPA and its underlying molecular mechanisms

详细信息    查看全文

• 作者：Chao Han^a ; ^&dagger ; ; Shuke Nie^a ; ^b ; ^&dagger ; ; Guiqin Chen^a ; Kai Ma^a ; Nian Xiong^a ; Zhentao Zhang^b ; Yan Xu^a ; ^{xuyanwxf@126.com} ; Tao Wang^a ; Stella M. Papa^c ; Xuebing Cao^a ; ^{caoxuebing@126.com}
• 关键词：AIMs ; abnormal involuntary movement scale ; ANOVA ; analysis of variance ; CPU ; striatum ; CREB ; cAMP response element-binding protein ; DARPP32 ; dopamine- and c-AMP-regulated phosphoprotein of 32  ; kDa ; DREAM ; calcium-binding protein downstream regulatory element antagonistic modulator ; ECL ; Electro-Chemi-Luminescence ; IHC ; immunohistochemistry ; LID ; l-DOPA-induced dyskinesia ; LTD ; long-term depression ; LTP ; long-term potentiation ; MFB ; medial forebrain bundle ; PD ; Parkinson&rsquo ; s disease ; p-ER
• 刊名：Neuroscience
• 出版年：2017
• 出版时间：6 January 2017
• 年：2017
• 卷：340
• 期：Complete
• 页码：23-33
• 全文大小：3431 K
• 卷排序：340

文摘

Ionomycin, a calcineurin activator, could attenuate l-DOPA-induced dyskinesia (LID) in hemiparkinsonian rats. Ionomycin downregulates ΔFosB and p-ERK that are markers of LID and the levels of DARPP-32 phosphorylated at Thr-34. Ionomycin reduces the phosphorylation level of p-NMDAR1 (ser896), p-NMDAR2A (Y1325) and p-NMDAR2B (Y1472). Both dopamine and glutamate signaling pathways play significant roles in the mechanisms of LID.